Research Articles | Page 72 | Aplastic Anemia & MDS International Foundation Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse Jul 2020 Blood Advances acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
Getting personal with myelodysplastic syndromes: is now the right time? Apr 2019 Expert Review of Hematology myelodysplastic syndromes (MDS)
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT Oct 2023 Lancet Hematology myelodysplastic syndromes (MDS)
Germline mutations in MDS/AML predisposition disorders Mar 2021 Current opinion in hematology acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
Germline DDX41 mutations define a significant entity within adult MDS/AML patients Sep 2019 Blood myelodysplastic syndromes (MDS)
Genomics of myelodysplastic/myeloproliferative neoplasm May 2023 Seminars in Diagnostic Pathology myelodysplastic syndromes (MDS)
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence Sep 2019 JCO Precision Oncology myelodysplastic syndromes (MDS)
Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity Sep 2014 Haematologica myelodysplastic syndromes (MDS)
Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy? Feb 2015 Expert Rev Hematol myelodysplastic syndromes (MDS)
Genetics of Progression From MDS to Secondary Leukemia Jul 2020 Blood myelodysplastic syndromes (MDS)
Share with addtoany.com.